法国输入性重症恶性疟:青蒿琥酯与奎宁倾向评分分析
该研究分析2011至2017年法国国家参考中心报告的所有重症输入性疟疾患者队列,采用逆概率治疗加权法控制混杂后比较奎宁与青蒿琥酯的28天死亡率及出院率。共纳入1544例,奎宁组460例死亡18例(3.9%),青蒿琥酯组1084例死亡32例(2.9%),两组死亡率(HR 1.03,95%CI 0.47-2.25)和出院率(HR 1.12,95%CI 0.94-1.34)无差异,但青蒿琥酯与更快的ICU出院率相关(HR 1.18,95%CI 1.02-1.36)。
要点
- 重症输入性疟疾中青蒿琥酯与奎宁的28天死亡率无显著差异。
- 青蒿琥酯组ICU出院更快(HR 1.18,95%CI 1.02-1.36)。
- 两组住院出院率无差异(HR 1.12,95%CI 0.94-1.34)。
核心结论
- 在高医疗水平国家,青蒿琥酯与更短的ICU住院时间相关,支持当前治疗转变,但死亡率或住院出院率与奎宁无差异。
研究设计与样本
- 分析2011至2017年法国国家参考中心报告的所有重症输入性疟疾患者队列,共纳入1544例。
- 采用逆概率治疗加权法控制奎宁组与青蒿琥酯组间差异,使用Kaplan-Meier估计和加权Cox比例风险模型比较28天死亡率及出院率。
主要发现
- 奎宁组460例中死亡18例(3.9%),青蒿琥酯组1084例中死亡32例(2.9%)。
- 奎宁与青蒿琥酯在死亡率上无差异,HR为1.03(95%CI 0.47-2.25)。
- 两组住院出院率无差异,HR为1.12(95%CI 0.94-1.34)。
- 青蒿琥酯与更快的ICU出院率相关,HR为1.18(95%CI 1.02-1.36)。
临床怎么用
- 在医疗水平较高的非流行国家,重症输入性恶性疟可优先考虑青蒿琥酯以缩短ICU住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known on the use of artesunate compared with quinine for the treatment of imported malaria cases in nonendemic countries with a high level of care. Therefore, we compared the 2 treatments in terms of mortality and hospital and intensive care unit (ICU) discharge rates. METHODS: We analyzed the cohort of all severe imported malaria patients reported to the French National Reference Center from 2011 to 2017. After controlling for differences between quinine- and artesunate-treated individuals using the inverse probability of treatment weighting method, 28-day mortality rate was compared between the groups as well as hospital and ICU discharge rates using Kaplan-Meier estimation and weighted Cox proportional hazard models. RESULTS: Overall, 1544 patients were enrolled. Fifty patients died, 18 in the quinine group (n = 460) and 32 in the artesunate group (n = 1084), corresponding to death rates of 3.9% and 2.9%, respectively. No difference was evident between quinine and artesunate either in mortality or in hospital discharge rate, with hazard ratios (HRs) of 1.03 (95% confidence interval [CI], 0.47-2.25) and 1.12 (95% CI, 0.94-1.34), respectively. Artesunate was associated with a faster ICU discharge rate (HR, 1.18. 95% CI, 1.02-1.36). CONCLUSIONS: In a country with a high level of care, artesunate was associated with a shorter length of stay in the ICU, which supports the actual therapeutic transition; however, no difference was found in terms of mortality or in hospital discharge rates between artesunate- and quinine-treated patients.
引用
- El Ket N, Kendjo E, Thellier M, et al. Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in France. Clin Infect Dis. 2020. PMID: 30874798. doi:10.1093/cid/ciz206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。